FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths / ABC News

go - The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

US narrows use of muscle-wasting therapy after teen deaths

4 months / medicalxpress

FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study

4 months / endpoints / Lei Lei Wu

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths

4 months / go

Saturday, November 15, 2025, 5:21 am / permalink 15991 / 3 stories in 4 months

Related Stories

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 6 wks
FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
FDA approves Rucaparib for advanced prostate cancer / 2 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 3 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 3 months
FDA Approves Ziftomenib for AML Treatment / 3 months
Experimental therapy reduces seizures in children with Dravet syndrome / 11 days

Related Tags

Healthcare

EPA proposes rollback on ethylene oxide sterilizer emissions (34 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (18 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (19 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (22 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (34 hrs)

more #pharmaceuticals

Public Health

EPA proposes rollback on ethylene oxide sterilizer emissions (34 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (21 hrs)

more #publichealth

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.